In 2020, our Cancer Program ranked 27th in the country in U.S. News and World Report and our GI Surgery Program ranked 21st. Our colon cancer surgery program was also deemed high performing for Adult Procedures and Conditions.
The General Surgery Residency Program remains one of the best in the country and provides operative experience with complex surgical oncology from patients with hepatobiliary, pancreatic, colorectal, and other gastrointestinal tumors, as well as breast, sarcoma, melanoma, and neuroendocrine malignancies.
Current research efforts include tissue and biomarker studies, development of new diagnostic devices and surgical techniques, and clinical trials for pharmaceutics and cancer immunotherapies.
The pancreatic clinical research program has led two NIH-funded investigator-initiated multicenter randomized clinical trials that impacted the use of drains during pancreatectomy, and the consequent development of a multicenter pancreatic surgery outcomes consortium.
The division leads an active, externally funded Surgical Translational Oncology Laboratory supported by a VA Merit Award with a focus on mechanisms of chemotherapy and radiation resistance in pancreatic and colorectal cancer.
Our basic science lab has studied the influence of gastrointestinal hormones on pancreatic cancer growth, the relationship between diabetes and pancreatic cancer, and genomic analysis of pancreatic cancer, resulting in hundreds of recent peer-reviewed publications.